Background: The most prevalent tumor marker for breast cancer is CS15-3. This marker’s elevated serum levels have been proven to predict a patient’s risk of developing the condition again. Purposes: The purpose of this study was to ascertain the sensitivity of blood CS15-3 levels in the identification of breast cancer recurrence. Patients and methods: A prospective cohort follow-up analytical study was conducted at Basra Oncology Center from early 2016 to the end of 2022. The study included 178 females aged ≥18 years with histologically confirmed invasive ductal breast cancer. CS15-3 had been evaluated for all included cases on two occasions: the first, at the time of diagnosis or remission, and the second, at the time of progression. The tumor marker (CS15-3) was evaluated using a Cobas e411 analyzer (Roche Diagnostics International Ltd). Results: The mean age showed no significant difference between the groups (P=0.581). The duration of progression was higher among those with the luminal group (40.60± 42.08). Those with bony and liver metastasis were mostly among luminal (50.0%) and HER 2+ (52.4%) groups respectively. At the time of diagnosis CS15-3 tumor marker showed no significant difference between the three groups, while at the time of progression, the luminal group showed higher means (120.74± 95.07) compared to others with a significant mean difference of (-99.84± 94.43). Conclusions: Age, disease stages, and co-morbidity have no significant influence on the distribution between groups of luminal. The duration of progression was higher among those in the luminal group. Osseous and hepatic secondaries are mostly among luminal and hormonal receptors positive. Initially, at the time of diagnosis CS15-3 marker expressed no significant difference between the groups, whereas at the time of progression, the luminal group expressed a higher means of level of the CS15-3 marker.
Salih, M., Al-Mansouri, L., & Hasson, H. (2024). Exploring the Prognostic Value of CS15-3 Tumor Marker in Breast Cancer Recurrence. Asian Pacific Journal of Cancer Prevention, 25(1), 229-232. doi: 10.31557/APJCP.2024.25.1.229
MLA
Maher Jabbar Salih; Loma Al-Mansouri; Hasson Mahdi Hasson. "Exploring the Prognostic Value of CS15-3 Tumor Marker in Breast Cancer Recurrence". Asian Pacific Journal of Cancer Prevention, 25, 1, 2024, 229-232. doi: 10.31557/APJCP.2024.25.1.229
HARVARD
Salih, M., Al-Mansouri, L., Hasson, H. (2024). 'Exploring the Prognostic Value of CS15-3 Tumor Marker in Breast Cancer Recurrence', Asian Pacific Journal of Cancer Prevention, 25(1), pp. 229-232. doi: 10.31557/APJCP.2024.25.1.229
VANCOUVER
Salih, M., Al-Mansouri, L., Hasson, H. Exploring the Prognostic Value of CS15-3 Tumor Marker in Breast Cancer Recurrence. Asian Pacific Journal of Cancer Prevention, 2024; 25(1): 229-232. doi: 10.31557/APJCP.2024.25.1.229
)